World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
33580
World Ranking
10463
National Ranking
329

Marc Sanson publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Marc Sanson sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 476 publications — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Marc Sanson D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Marc Sanson sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 94 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Marc Sanson is affiliated with Sorbonne University in France. Their research primarily focuses on the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Within these areas, they have contributed extensively to Genetics, Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine, and Radiology, Nuclear Medicine and Imaging.

The scientist's work covers a range of topics related to neurological and oncological conditions, with a significant emphasis on glioma diagnosis and treatment. Other main topics include radiomics and machine learning in medical imaging, cancer genomics and diagnostics, management of meningioma and schwannoma, cancer, hypoxia, and metabolism, brain metastases and treatment, and ferroptosis and cancer prognosis.

Marc Sanson has been published frequently in various scientific journals. The venues where they have the most publications include:

  • Neuro-Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cancer Research
  • Journal of Clinical Oncology
  • Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition

They have collaborated repeatedly with a number of coauthors:

  • Franck Bielle
  • Ahmed Idbaïh
  • Alberto Pïcca
  • Anna Luisa Di Stefano
  • Mehdi Touat

Notable recent papers include:

  • "Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions," 2020, Neuro-Oncology
  • "Mechanisms and therapeutic implications of hypermutation in gliomas," 2020, Nature
  • "Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities," 2021, Nature Cancer
  • "Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study," 2021, The Lancet Oncology
  • "Challenges in glioblastoma research: focus on the tumor microenvironment," 2022, Trends in cancer

Best Publications

  • Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2

    Guy A. Rouleau;Philippe Merel;Mohini Lutchman;Marc Sanson;Marc Sanson

  • Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

    Marc Sanson;Yannick Marie;Sophie Paris;Ahmed Idbaih

  • Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial

    Martin J. van den Bent;Antoine F. Carpentier;Alba A. Brandes;Marc Sanson

  • Genome-wide association study identifies five susceptibility loci for glioma

    Sanjay Shete;Fay J. Hosking;Lindsay B. Robertson;Sara E. Dobbins

  • Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

    Patrick Y. Wen;Michael Weller;Eudocia Quant Lee;Brian M. Alexander

  • Clinical trial of blood-brain barrier disruption by pulsed ultrasound

    Alexandre Carpentier;Michael Canney;Alexandre Vignot;Vincent Reina

  • Mechanisms and therapeutic implications of hypermutation in gliomas.

    Mehdi Touat;Mehdi Touat;Mehdi Touat;Yvonne Y. Li;Yvonne Y. Li;Adam N. Boynton;Adam N. Boynton;Liam F. Spurr;Liam F. Spurr

  • IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas

    C. Houillier;X. Wang;G. Kaloshi;K. Mokhtari

  • MGMT testing—the challenges for biomarker-based glioma treatment

    Wolfgang Wick;Michael Weller;Martin van den Bent;Marc Sanson

  • A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry.

    Soufiane El Hallani;Blandine Boisselier;Florent Peglion;Audrey Rousseau

  • Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

    Martin J van den Bent;Brigitta Baumert;Sara C Erridge;Michael A Vogelbaum;Michael A Vogelbaum

  • Glioblastoma targeted therapy: updated approaches from recent biological insights

    M. Touat;M. Touat;A. Idbaih;M. Sanson;K.L. Ligon

  • Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p Deletions

    K. Hoang-Xuan;L. Capelle;M. Kujas;S. Taillibert

  • Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire

    Carole Soussain;Khê Hoang-Xuan;Luc Taillandier;Emmanuelle Fourme

  • IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

    Martin J. van den Bent;Hendrikus J. Dubbink;Yannick Marie;Alba A. Brandes

  • MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951

    Martin J. van den Bent;Hendrikus J. Dubbink;Marc Sanson;Cathleen R. van der Lee-Haarloo

  • Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients.

    Jean-Sébastien Guillamo;Alain Créange;Chantal Kalifa;Jacques Grill

  • Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors

    Beatrice S Melin;Jill S Barnholtz-Sloan;Margaret R Wrensch;Christoffer Johansen

  • Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome

    G. Kaloshi;A. Benouaich-Amiel;F. Diakite;S. Taillibert

  • All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2

    M. Labussière;A. Idbaih;X.-W. Wang;Y. Marie

Frequent Co-Authors

Khê Hoang-Xuan
Khê Hoang-Xuan Université Paris Cité
Ahmed Idbaih
Ahmed Idbaih Sorbonne University
Jean-Yves Delattre
Jean-Yves Delattre Université Paris Cité
Martin J. van den Bent
Martin J. van den Bent Erasmus University Rotterdam
Olivier Delattre
Olivier Delattre PSL University
Dominique Figarella-Branger
Dominique Figarella-Branger Aix-Marseille University
Johan M. Kros
Johan M. Kros Erasmus University Rotterdam
Pieter Wesseling
Pieter Wesseling University of Amsterdam
Gilles Thomas
Gilles Thomas Grenoble Alpes University
Richard S. Houlston
Richard S. Houlston Institute of Cancer Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn’t always mean taking the traditional route to an MD. There are a variety of online degree programs and career pathways for those interested in healthcare, offering both flexibility and speed. For nursing professionals seeking career advancement, the easiest online dnp programs can help practicing nurses gain leadership positions while managing work and life responsibilities.

If you’re considering starting your healthcare career quickly, lpn online programs let you become a Licensed Practical Nurse in less time, providing essential skills for working directly with patients. For those interested in mental health, specialized online programs like the psych np programs prepare nurses for psychiatric and mental health nurse practitioner roles, an area in high demand.

Alternatively, for a leadership role outside of direct patient care, an online health management degree opens doors to administrative and executive opportunities within healthcare organizations. These options allow students to tailor their educational journeys to align with their career goals and personal circumstances.

Best Scientists Citing Marc Sanson

Trending Scientists

Recently Published Articles